Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Bevacizumab, Radiation Therapy, and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Locally Advanced Nonmetastatic Rectal Cancer

13 maart 2019 bijgewerkt door: National Cancer Institute (NCI)

Phase II Study of Preoperative Radiation With Concurrent Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab in Patients With Locally Advanced Rectal Cancer

This phase II trial studies how well giving bevacizumab, radiation therapy, and combination chemotherapy works in treating patients who are undergoing surgery for locally advanced nonmetastatic rectal cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some find tumor cells and kill them or carry tumor-killing substances to them. Others interfere with the ability of tumor cells to grow and spread. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs, such as capecitabine, may make tumor cells more sensitive to radiation therapy. Drugs used in chemotherapy, such as capecitabine, oxaliplatin, fluorouracil, and leucovorin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with radiation therapy and combination chemotherapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. Giving bevacizumab together with combination chemotherapy after surgery may kill any tumor cells that remain after surgery.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

PRIMARY OBJECTIVES:

I. To evaluate the pathological complete response rate in patients with T3 and T4 rectal cancers when treated preoperatively with capecitabine, oxaliplatin, bevacizumab, and concurrent radiotherapy (XRT).

II. To evaluate the resection rate for T3 and T4 rectal cancers and the expected versus actual type of resection (abdominoperinal resection [APR] vs. low anterior resection [LAR] vs. LAR/coloanal anastomosis).

III. To make preliminary observations of patient survival and patterns of recurrence for this treatment combination.

IV. To gain additional experience regarding the toxicity and tolerability of this preoperative and postoperative regimen.

OUTLINE:

PREOPERATIVE CHEMORADIOTHERAPY: Patients undergo radiotherapy (total dose to the tumor bed was 5040 cGy) once daily (QD) 5 days a week and receive capecitabine 825 mg/m^2 orally (PO) twice daily (BID) 5 days a week for 5.5 weeks. Patients also receive oxaliplatin 50 mg/m^2 intravenously (IV) over 2 hours on days 1, 8, 15, 22, and 29 and bevacizumab 5 mg/kg IV over 30-90 minutes on days 1, 15, and 29 during radiotherapy.

SURGERY: Approximately 6-8 weeks after completion of chemoradiotherapy, patients undergo surgical resection. Patients whose tumors are not completely resected or who have metastatic disease discontinue protocol therapy.

POSTOPERATIVE CHEMOTHERAPY: Approximately 4-12 weeks after surgery, patients receive oxaliplatin IV over 2 hours, leucovorin calcium 400 mg/m^2 IV over 2 hours, and bevacizumab 5 mg/kg IV over 30-90 minutes on day 1. Patients also receive fluorouracil 2400 mg/m^2 IV continuously over 46 hours beginning on day 1. Treatment repeats every 2 weeks for 9 courses in the absence of disease progression or unacceptable toxicity. Patients then receive up to 3 additional courses of leucovorin calcium, fluorouracil, and bevacizumab.

After completion of study treatment, patients are followed up periodically for 10 years.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

57

Fase

  • Fase 2

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

  • Verenigde Staten
    • Alabama
      • Birmingham, Alabama, Verenigde Staten, 35233
        • University of Alabama at Birmingham Cancer Center
    • Connecticut
      • New Britain, Connecticut, Verenigde Staten, 06050
        • The Hospital of Central Connecticut
    • Georgia
      • Atlanta, Georgia, Verenigde Staten, 30322
        • Emory University Hospital/Winship Cancer Institute
      • Decatur, Georgia, Verenigde Staten, 30033
        • Atlanta VA Medical Center
      • Macon, Georgia, Verenigde Staten, 31201
        • Medical Center of Central Georgia
    • Illinois
      • Aurora, Illinois, Verenigde Staten, 60504
        • Rush - Copley Medical Center
      • Berwyn, Illinois, Verenigde Staten, 60402
        • MacNeal Hospital and Cancer Center
      • Chicago, Illinois, Verenigde Staten, 60611
        • Northwestern University
      • Chicago, Illinois, Verenigde Staten, 60625
        • Swedish Covenant Hospital
      • Chicago, Illinois, Verenigde Staten, 60611
        • Hematology and Oncology Associates
      • Chicago, Illinois, Verenigde Staten, 60657
        • Presence Saint Joseph Hospital-Chicago
      • Chicago, Illinois, Verenigde Staten, 60612
        • Jesse Brown Veterans Affairs Medical Center
      • Chicago, Illinois, Verenigde Staten, 60616
        • Mercy Hospital and Medical Center
      • Effingham, Illinois, Verenigde Staten, 62401
        • Saint Anthony Memorial Hospital
      • Highland Park, Illinois, Verenigde Staten, 60035
        • Hematology Oncology Associates of Illinois-Highland Park
      • Hinsdale, Illinois, Verenigde Staten, 60521
        • Hinsdale Hematology Oncology Associates Incorporated
      • Joliet, Illinois, Verenigde Staten, 60435
        • Joliet Oncology-Hematology Associates Limited
      • Joliet, Illinois, Verenigde Staten, 60432
        • Midwest Center for Hematology Oncology
      • Libertyville, Illinois, Verenigde Staten, 60048
        • NorthShore Hematology Oncology-Libertyville
      • Moline, Illinois, Verenigde Staten, 61265
        • Garneau, Stewart C MD (UIA Investigator)
      • Moline, Illinois, Verenigde Staten, 61265
        • Porubcin, Michael MD (UIA Investigator)
      • Moline, Illinois, Verenigde Staten, 61265
        • Spector, David MD (UIA Investigator)
      • Moline, Illinois, Verenigde Staten, 61265
        • Trinity Medical Center
      • Moline, Illinois, Verenigde Staten, 61265
        • Sharis, Christine M MD (UIA Investigator)
      • Moline, Illinois, Verenigde Staten, 61265
        • Stoffel, Thomas J MD (UIA Investigator)
      • Moline, Illinois, Verenigde Staten, 61265
        • Vigliotti, Antonio, P.G. M.D. (UIA Investigator)
      • Naperville, Illinois, Verenigde Staten, 60563
        • DuPage Medical Group-Ogden
      • Niles, Illinois, Verenigde Staten, 60714
        • Illinois Cancer Specialists-Niles
      • Skokie, Illinois, Verenigde Staten, 60076
        • Hematology Oncology Associates of Illinois - Skokie
      • Skokie, Illinois, Verenigde Staten, 60076
        • Edward H Kaplan MD and Associates
      • Urbana, Illinois, Verenigde Staten, 61801
        • Carle Cancer Center
    • Indiana
      • Michigan City, Indiana, Verenigde Staten, 46360
        • Franciscan Saint Anthony Health-Michigan City
    • Iowa
      • Bettendorf, Iowa, Verenigde Staten, 52722
        • Constantinou, Costas L MD (UIA Investigator)
      • Sioux City, Iowa, Verenigde Staten, 51101
        • Siouxland Regional Cancer Center
      • Sioux City, Iowa, Verenigde Staten, 51102
        • Mercy Medical Center-Sioux City
      • Sioux City, Iowa, Verenigde Staten, 51104
        • Saint Luke's Regional Medical Center
    • Michigan
      • Kalamazoo, Michigan, Verenigde Staten, 49007
        • West Michigan Cancer Center
      • Kalamazoo, Michigan, Verenigde Staten, 49007
        • Bronson Methodist Hospital
      • Kalamazoo, Michigan, Verenigde Staten, 49048
        • Borgess Medical Center
    • Minnesota
      • Burnsville, Minnesota, Verenigde Staten, 55337
        • Fairview Ridges Hospital
      • Coon Rapids, Minnesota, Verenigde Staten, 55433
        • Mercy Hospital
      • Edina, Minnesota, Verenigde Staten, 55435
        • Fairview-Southdale Hospital
      • Fridley, Minnesota, Verenigde Staten, 55432
        • Unity Hospital
      • Hutchinson, Minnesota, Verenigde Staten, 55350
        • Hutchinson Area Health Care
      • Litchfield, Minnesota, Verenigde Staten, 55355
        • Meeker County Memorial Hospital
      • Maplewood, Minnesota, Verenigde Staten, 55109
        • Saint John's Hospital - Healtheast
      • Maplewood, Minnesota, Verenigde Staten, 55109
        • Minnesota Oncology Hematology PA-Maplewood
      • Minneapolis, Minnesota, Verenigde Staten, 55415
        • Hennepin County Medical Center
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Abbott-Northwestern Hospital
      • Minneapolis, Minnesota, Verenigde Staten, 55407
        • Virginia Piper Cancer Institute
      • Robbinsdale, Minnesota, Verenigde Staten, 55422
        • North Memorial Medical Health Center
      • Saint Louis Park, Minnesota, Verenigde Staten, 55416
        • Park Nicollet Clinic - Saint Louis Park
      • Saint Louis Park, Minnesota, Verenigde Staten, 55416
        • Metro Minnesota Community Oncology Research Consortium
      • Saint Paul, Minnesota, Verenigde Staten, 55101
        • Regions Hospital
      • Saint Paul, Minnesota, Verenigde Staten, 55102
        • United Hospital
      • Saint Paul, Minnesota, Verenigde Staten, 55102
        • Saint Joseph's Hospital - Healtheast
      • Shakopee, Minnesota, Verenigde Staten, 55379
        • Saint Francis Regional Medical Center
      • Waconia, Minnesota, Verenigde Staten, 55387
        • Ridgeview Medical Center
      • Woodbury, Minnesota, Verenigde Staten, 55125
        • Minnesota Oncology Hematology PA-Woodbury
      • Woodbury, Minnesota, Verenigde Staten, 55125
        • Woodwinds Health Campus
    • Nebraska
      • Lincoln, Nebraska, Verenigde Staten, 68510
        • Nebraska Cancer Research Center
      • Omaha, Nebraska, Verenigde Staten, 68124
        • Alegent Health Bergan Mercy Medical Center
      • Omaha, Nebraska, Verenigde Staten, 68122
        • Alegent Health Immanuel Medical Center
      • Omaha, Nebraska, Verenigde Staten, 68131
        • Creighton University Medical Center
      • Omaha, Nebraska, Verenigde Staten, 68106
        • Missouri Valley Cancer Consortium
    • New Jersey
      • Mount Holly, New Jersey, Verenigde Staten, 08060
        • Virtua Memorial
      • Sparta, New Jersey, Verenigde Staten, 07871
        • Sparta Cancer Treatment Center
      • Voorhees, New Jersey, Verenigde Staten, 08043
        • Virtua Voorhees
      • Woodbury, New Jersey, Verenigde Staten, 08096
        • Inspira Medical Center Woodbury
    • New York
      • Bronx, New York, Verenigde Staten, 10467
        • Montefiore Medical Center - Moses Campus
      • Bronx, New York, Verenigde Staten, 10466
        • Montefiore Medical Center-Wakefield Campus
    • Ohio
      • Akron, Ohio, Verenigde Staten, 44304
        • Summa Akron City Hospital/Cooper Cancer Center
      • Barberton, Ohio, Verenigde Staten, 44203
        • Summa Barberton Hospital
      • Bellefontaine, Ohio, Verenigde Staten, 43311
        • Mary Rutan Hospital
      • Chillicothe, Ohio, Verenigde Staten, 45601
        • Adena Regional Medical Center
      • Columbus, Ohio, Verenigde Staten, 43214
        • Riverside Methodist Hospital
      • Columbus, Ohio, Verenigde Staten, 43228
        • Doctors Hospital
      • Columbus, Ohio, Verenigde Staten, 43215
        • Grant Medical Center
      • Columbus, Ohio, Verenigde Staten, 43222
        • Mount Carmel Health Center West
      • Delaware, Ohio, Verenigde Staten, 43015
        • Grady Memorial Hospital
      • Lancaster, Ohio, Verenigde Staten, 43130
        • Fairfield Medical Center
      • Lima, Ohio, Verenigde Staten, 45801
        • Saint Rita's Medical Center
      • Marietta, Ohio, Verenigde Staten, 45750
        • Marietta Memorial Hospital
      • Newark, Ohio, Verenigde Staten, 43055
        • Licking Memorial Hospital
      • Springfield, Ohio, Verenigde Staten, 45505
        • Springfield Regional Medical Center
      • Westerville, Ohio, Verenigde Staten, 43081
        • Saint Ann's Hospital
      • Zanesville, Ohio, Verenigde Staten, 43701
        • Genesis Healthcare System Cancer Care Center
    • Oklahoma
      • Tulsa, Oklahoma, Verenigde Staten, 74136
        • Natalie Warren Bryant Cancer Center at Saint Francis
    • Pennsylvania
      • Allentown, Pennsylvania, Verenigde Staten, 18103
        • Lehigh Valley Hospital-Cedar Crest
      • Darby, Pennsylvania, Verenigde Staten, 19023-1291
        • Mercy Fitzgerald Hospital
      • East Stroudsburg, Pennsylvania, Verenigde Staten, 18301
        • Pocono Medical Center
      • Ephrata, Pennsylvania, Verenigde Staten, 17522
        • Ephrata Cancer Center
      • Media, Pennsylvania, Verenigde Staten, 19063
        • Riddle Memorial Hospital
      • Philadelphia, Pennsylvania, Verenigde Staten, 19111
        • Fox Chase Cancer Center
      • Philadelphia, Pennsylvania, Verenigde Staten, 19107
        • Thomas Jefferson University Hospital
      • Philadelphia, Pennsylvania, Verenigde Staten, 19141
        • Einstein Medical Center Philadelphia
      • Philadelphia, Pennsylvania, Verenigde Staten, 19114
        • Aria Health-Torresdale Campus
      • Scranton, Pennsylvania, Verenigde Staten, 18508
        • Hematology and Oncology Associates of North East Pennsylvania
      • Upland, Pennsylvania, Verenigde Staten, 19013
        • Associates In Hematology Oncology PC-Upland
    • South Dakota
      • Sioux Falls, South Dakota, Verenigde Staten, 57105
        • Avera Cancer Institute
      • Sioux Falls, South Dakota, Verenigde Staten, 57117-5134
        • Sanford USD Medical Center - Sioux Falls
      • Sioux Falls, South Dakota, Verenigde Staten, 57104
        • Sanford Cancer Center Oncology Clinic
      • Sioux Falls, South Dakota, Verenigde Staten, 57105
        • Medical X-Ray Center
      • Sioux Falls, South Dakota, Verenigde Staten, 57105
        • Avera McKennan Hospital and University Health Center
    • Texas
      • Dallas, Texas, Verenigde Staten, 75390
        • UT Southwestern/Simmons Cancer Center-Dallas
    • Wisconsin
      • La Crosse, Wisconsin, Verenigde Staten, 54601
        • Gundersen Lutheran Medical Center
      • Milwaukee, Wisconsin, Verenigde Staten, 53226
        • Froedtert and The Medical College of Wisconsin

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  • Patients must have histologically confirmed, locally advanced, non-metastatic primary T3 or T4 adenocarcinoma of the rectum
  • Patients must not have evidence of tumor outside of the pelvis including liver metastases, peritoneal seeding, or metastatic inguinal lymphadenopathy
  • Patients must not have intra-operative radiotherapy (IORT) or brachytherapy treatment to the pelvis
  • The distal border of the tumor must be at or below the peritoneal reflection, defined as within 12 centimeters of the anal verge by proctoscopic examination
  • Transmural penetration of tumor through the muscularis propria must be demonstrated by either of the following: computed tomography (CT) scan plus endorectal ultrasound, or a magnetic resonance imaging (MRI); an endorectal coil or pelvic MRI is allowed
  • For the patient to be eligible, the surgeon must prospectively define the tumor as either initially resectable or potentially resectable after pre-operative chemoradiation; clinically resectable tumors are defined as completely resectable with negative margins based on routine examination of the non-anesthetized patient; patients whose tumors are not resectable are not eligible; before pre-operative (op) treatment, the surgeon should estimate and record the type of resection anticipated: pelvic exenteration, posterior pelvic exenteration, APR, LAR, or LAR/coloanal anastomosis

  • Patients with tumors that are clinically fixed, clinical stage T4N0-2, M0 are eligible if it is believed that their tumors are potentially resectable after chemoradiation; based on the following:

    • Clinically fixed tumors on rectal examination with tumor adherent to the pelvic sidewall or sacrum
    • Sciatica attributed to sacral root invasion with CT scan/MRI evidence of the lack of clear tissue plane will be considered evidence of fixation
    • Hydronephrosis on CT scan or intravenous pyelogram (IVP) or ureteric or bladder invasion as documented by cystoscopy and cytology or biopsy, or invasion into prostate
    • Vaginal or uterine involvement
  • Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-1
  • A surgical evaluation must confirm patient's ability to tolerate the proposed surgical procedure
  • Patients must have a caloric intake > 1500 kilocalories/day (d)
  • Within 4 weeks prior to registration, the patient's absolute neutrophil count (ANC) level must be >= 1,500/mm^3
  • Within 4 weeks prior to registration, the patients platelet level must be >= 100,000/mm^3
  • Within 4 weeks prior to registration, serum creatinine must be < 1.5 X upper limit of normal (ULN); if serum creatinine > 1.5 x ULN, then creatinine clearance must be >= 50 mL/mm
  • Within 4 weeks prior to registration, serum bilirubin must be =< 1.5 X ULN
  • Within 4 weeks prior to registration, alkaline phosphatase (alk phos) must be < 2 x ULN
  • Within 4 weeks prior to registration, serum glutamic oxaloacetic transaminase (SGOT) must be < 2 x ULN
  • Carcinoembryonic antigen (CEA) must be determined prior to initiation of therapy
  • Within 4 weeks prior to registration, urine protein/creatinine (UPC) ratio must be < 1; patients with a ratio of >= 1 must undergo a 24-hour urine collection which must be an adequate collection and must demonstrate < 1 gram (gm) of protein in order to participate
  • Within 4 weeks prior to registration, albumin must be >= 2 gm/dl
  • Absence of clinical evidence of high-grade (lumen diameter < 1 cm) large bowel obstruction, unless diverting colostomy has been performed
  • Eligible patients of reproductive potential (both sexes) must agree to use an accepted and effective method of contraceptive during study therapy and for at least 6 months after the completion of bevacizumab
  • Women must not be pregnant or breast-feeding; all females of childbearing potential must have a serum pregnancy test to rule out pregnancy within 2 weeks of registration
  • Patients must have had no prior chemotherapy for rectal cancer or pelvic irradiation therapy
  • Patients with prior malignancies, including pelvic cancer, are eligible if they have been disease free for > 5 years; patients with prior in situ carcinomas are eligible provided there was complete removal
  • Patients must have no active inflammatory bowel disease or other serious medical illness or disease that might limit the patient's ability to receive protocol therapy
  • Patients with a history of cerebrovascular accident (CVA)/transient ischemic attack (TIA) at any time, or myocardial infarction/unstable angina within 12 months of study entry are not eligible
  • Patients with > grade 1 peripheral neuropathy are not eligible
  • Patients must have urine protein/creatinine (UPC) ratio of < 1.0; patients with a UPC ratio >= 1.0 must undergo a 24-hour urine collection, which must be an adequate collection and must demonstrate < 1 gm of protein in order to participate
  • Patients with a history of hypertension must measure < 150/90 mmHg and be on a stable regimen of anti-hypertensive therapy
  • Patients with clinically significant peripheral vascular disease are not eligible

  • Patients must not have any of the following:

    • Unstable angina (within 12 months of study entry)
    • New York Heart Association (NYHA) grade II or higher congestive heart failure
    • Evidence of bleeding diathesis/coagulopathy
    • Serious non-healing wound or bone fracture

  • Patients with a history of the following within 28 days prior to registration are not eligible:

    • Abdominal fistula
    • Gastrointestinal perforation
    • Intrabdominal abscess

  • Patients with a history of the following within 28 days prior to day 0 (first treatment day) are not eligible:

    • Major surgical procedure
    • Open biopsy
    • Significant traumatic injury
  • Patients must not have core biopsy within 7 days prior to day 0 (first treatment day)

  • Patients with prothrombin time (PT) (international normalized ratio [INR]) > 1.5 are not eligible, unless the patient is on full-dose anticoagulants; if so, the following criteria must be met for enrollment:

    • The subject must have an in-range INR (usually between 2 and 3), be on a stable dose of warfarin or on a stable dose of low molecular weight heparin
    • The subject must not have active bleeding or a pathological condition that is associated with a high risk of bleeding

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treatment (bevacizumab and chemoradiotherapy)
See Detailed Description
Biologisch: Bevacizumab
IV gegeven
Andere namen:
  • Avastin
  • Anti-VEGF
  • Anti-VEGF gehumaniseerd monoklonaal antilichaam
  • Anti-VEGF rhuMAb
  • Bevacizumab Biosimilar BEVZ92
  • Bevacizumab Biosimilar BI 695502
  • Bevacizumab Biosimilar CBT 124
  • Bevacizumab Biosimilar FKB238
  • Bevacizumab Biosimilar MIL60
  • Bevacizumab Biosimilar QL 1101
  • Immunoglobuline G1 (mens-muis monoklonaal rhuMab-VEGF gamma-keten anti-menselijke vasculaire endotheliale groeifactor), disulfide met mens-muis monoklonaal rhuMab-VEGF lichte keten, dimeer
  • Recombinant gehumaniseerd anti-VEGF monoklonaal antilichaam
  • rhuMab-VEGF
  • BEVACIZUMAB, LICENTIEHOUDER NIET GESPECIFICEERD
Geneesmiddel: Fluoruracil
IV gegeven
Andere namen:
  • 5-FU
  • 5-Fluracil
  • Fluracil
  • 5-Fluor-2,4(1H,3H)-pyrimidinedion
  • 5-Fluorouracil
  • AccuSite
  • Carac
  • Fluor Uracil
  • Fluoracil
  • Flurablastine
  • Fluracedyl
  • Fluril
  • Fluroblastine
  • Ribofluor
  • Ro 2-9757
  • Ro-2-9757
Geneesmiddel: Oxaliplatine
IV gegeven
Andere namen:
  • 1-OHP
  • Dacotin
  • Dacplat
  • Eloxatin
  • Ai Heng
  • Aiheng
  • Diaminocyclohexaan Oxalatoplatina
  • Eloxatine
  • JM-83
  • Oxalatoplatine
  • Oxalatoplatina
  • RP 54780
  • RP-54780
  • SR-96669
Geneesmiddel: Capecitabine
Gegeven PO
Andere namen:
  • Xeloda
  • Ro 09-1978/000
Geneesmiddel: Leucovorin Calcium
IV gegeven
Andere namen:
  • Welcovorin
  • citrovorum-factor
  • folinezuur
  • Adinepar
  • Calcifolin
  • Calcium (6S)-folinaat
  • Calciumfolinaat
  • Calcium leucovorine
  • Calfolex
  • Calinat
  • Cehafolin
  • Citofolin
  • Citrec
  • Cromatonbische Folinico
  • Dalisol
  • Disintox
  • Divicaal
  • Ecofol
  • Emovis
  • Factor, Citrovorum
  • Flynoken A
  • Folaren
  • Folaxin
  • FOLI-cel
  • Foliben
  • Folidan
  • Bladerdeeg
  • Folinac
  • Folinaat Calcium
  • Folinezuur Calciumzout Pentahydraat
  • Folinoraal
  • Folinvit
  • Foliplus
  • Folix
  • Imo
  • Lederfolaat
  • Lederfolin
  • Leucosar
  • leucovorine
  • Rescufolin
  • Rescuvolin
  • Tonofolin
Procedure: Therapeutische conventionele chirurgie
Onderga chirurgische resectie
Straling: Bestralingstherapie
Radiotherapie ondergaan
Andere namen:
  • Radiotherapie bij kanker
  • Bestralen
  • Bestraald
  • Straling
  • Radiotherapie
  • RT
  • Therapie, bestraling
  • bestraling
  • RADIOTHERAPIE

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Pathologic Complete Response Rate
Tijdsspanne: Assessed at surgery time
Pathologic complete response to preoperative therapy was determined at the time of surgical resection. Pathologic complete response (pCR) is defined as no evidence of invasive cells on pathologic examination of the primary rectal cancer (or tissue from the area where the tumor had been if there is a complete clinical response). Pathologic complete response rate is calculated as number of patients achieving pathologic complete response divided by all eligible and treated patients
Assessed at surgery time

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Resection Rate for T3 Rectal Cancers
Tijdsspanne: Assessed at surgery time
Resection rate is defined as number of patients with T3 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T3 rectal cancers
Assessed at surgery time
Resection Rate for T4 Rectal Cancers
Tijdsspanne: Assessed at surgery time
Resection rate is defined as number of patients with T4 rectal cancer who underwent curative surgical resection among all eligible and treated patients with T4 rectal cancers
Assessed at surgery time
5-year Overall Survival Rate
Tijdsspanne: survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
Overall survival is defined as time from registration to death from any cause. 5-year overall survival rate is estimated using Kaplan-Meier method.
survival follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
5-year Recurrence-free Survival Rate
Tijdsspanne: recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration
Recurrence free survival is defined as time from surgery to disease recurrence or death without recurrence (whichever occurred first) among resected patients. 5-year recurrence-free survival rate is estimated using Kaplan-Meier method, with 90% confidence interval calculated using Greenwood's formula.
recurrence follow-up began after post-operative chemotherapy, assessed every 3 months for patients 3-5 years from registration, every 6 months for patients 5-10 years from registration and every 12 months for patients 10 years from registration

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

National Cancer Institute (NCI)

Onderzoekers

  • Hoofdonderzoeker: Jerome C Landry, ECOG-ACRIN Cancer Research Group

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Algemene publicaties

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 juli 2006

Primaire voltooiing (Werkelijk)

12 augustus 2013

Studie voltooiing (Werkelijk)

11 februari 2019

Studieregistratiedata

Eerst ingediend

2 mei 2006

Eerst ingediend dat voldeed aan de QC-criteria

2 mei 2006

Eerst geplaatst (Schatting)

4 mei 2006

Updates van studierecords

Laatste update geplaatst (Werkelijk)

27 maart 2019

Laatste update ingediend die voldeed aan QC-criteria

13 maart 2019

Laatst geverifieerd

1 maart 2019

Meer informatie

Termen gerelateerd aan deze studie

Aanvullende relevante MeSH-voorwaarden

Andere studie-ID-nummers

  • NCI-2009-01081 (Register-ID: CTRP (Clinical Trial Reporting Program))
  • U10CA180820 (Subsidie/contract van de Amerikaanse NIH)
  • U10CA021115 (Subsidie/contract van de Amerikaanse NIH)
  • CDR0000471148
  • ECOG-E3204
  • E3204 (Andere identificatie: CTEP)

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren